Trial Profile
Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Mosedipimod (Primary)
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Enzychem Lifesciences Corporation
- 08 Feb 2022 Status changed from recruiting to completed.
- 08 Jan 2021 According to an Enzychem Lifesciences Corporation media release, the company expect to report results from this trial in the first half of this year.
- 13 Jul 2020 Status changed from planning to recruiting, according to an Enzychem Lifesciences Corporation media release.